CureVac N.V. (CVAC)
CureVac Statistics
Share Statistics
CureVac has 224.31M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 224.31M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 3.5% |
| Shares Floating | 93.99M |
| Failed to Deliver (FTD) Shares | 74.41K |
| FTD / Avg. Volume | 11.78% |
Short Selling Information
The latest short interest is 4.85M, so 2.16% of the outstanding shares have been sold short.
| Short Interest | 4.85M |
| Short % of Shares Out | 2.16% |
| Short % of Float | 12.09% |
| Short Ratio (days to cover) | 7.29 |
Valuation Ratios
The PE ratio is 4.56 and the forward PE ratio is -10.98. CureVac's PEG ratio is -0.03.
| PE Ratio | 4.56 |
| Forward PE | -10.98 |
| PS Ratio | 1.38 |
| Forward PS | 4.9 |
| PB Ratio | 1.06 |
| P/FCF Ratio | 8.86 |
| PEG Ratio | -0.03 |
Enterprise Valuation
CureVac has an Enterprise Value (EV) of 296.1M.
| EV / Sales | 0.55 |
| EV / EBITDA | 1.41 |
| EV / EBIT | 2.91 |
| EV / FCF | 3.55 |
Financial Position
The company has a current ratio of 7.28, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.28 |
| Quick Ratio | 7.27 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.19 |
| Debt / FCF | 0.47 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 23.28% and Return on Invested Capital is 20.52%.
| Return on Equity | 23.28% |
| Return on Assets | 20.2% |
| Return on Invested Capital | 20.52% |
| Revenue Per Employee | $648.7K |
| Profits Per Employee | $196.59K |
| Employee Count | 825 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 195.62 |
Taxes
| Income Tax | 28.7M |
| Effective Tax Rate | 15.03% |
Stock Price Statistics
The stock price has increased by 41.56% in the last 52 weeks. The beta is 2.48, so CureVac's price volatility has been higher than the market average.
| Beta | 2.48 |
| 52-Week Price Change | 41.56% |
| 50-Day Moving Average | 3.09 |
| 200-Day Moving Average | 3.19 |
| Relative Strength Index (RSI) | 57.71 |
| Average Volume (20 Days) | 631.9K |
Income Statement
In the last 12 months, CureVac had revenue of 535.18M and earned 162.19M in profits. Earnings per share was 0.7.
| Revenue | 535.18M |
| Gross Profit | 429.35M |
| Operating Income | 177.68M |
| Net Income | 162.19M |
| EBITDA | 209.69M |
| EBIT | 190.88M |
| Earnings Per Share (EPS) | 0.7 |
Balance Sheet
The company has 481.75M in cash and 38.97M in debt, giving a net cash position of 442.78M.
| Cash & Cash Equivalents | 481.75M |
| Total Debt | 38.97M |
| Net Cash | 442.78M |
| Retained Earnings | -1.4B |
| Total Assets | 802.83M |
| Working Capital | 454.07M |
Cash Flow
In the last 12 months, operating cash flow was 101.85M and capital expenditures -18.44M, giving a free cash flow of 83.41M.
| Operating Cash Flow | 101.85M |
| Capital Expenditures | -18.44M |
| Free Cash Flow | 83.41M |
| FCF Per Share | 0.37 |
Margins
Gross margin is 80.23%, with operating and profit margins of 33.2% and 30.3%.
| Gross Margin | 80.23% |
| Operating Margin | 33.2% |
| Pretax Margin | 35.67% |
| Profit Margin | 30.3% |
| EBITDA Margin | 39.18% |
| EBIT Margin | 33.2% |
| FCF Margin | 15.58% |
Dividends & Yields
CVAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 21.95% |
| FCF Yield | 11.29% |
Analyst Forecast
The average price target for CVAC is $10, which is 205.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $10 |
| Price Target Difference | 205.8% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 3.73 |
| Piotroski F-Score | 7 |